Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S.
Hall MS, et al. Among authors: rodriguez valentin m.
J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288.
J Immunother Cancer. 2023.
PMID: 37802604
Free PMC article.